Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211


Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.

Okamoto T, Kohno M, Ito K, Takada K, Katsura M, Morodomi Y, Toyokawa G, Shoji F, Maehara Y.

Anticancer Res. 2017 Apr;37(4):1729-1735.


Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.

Cortot AB, Younes M, Martel-Planche G, Guibert B, Isaac S, Souquet PJ, Commo F, Girard P, Fouret P, Brambilla E, Hainaut P, Soria JC.

Clin Lung Cancer. 2014 Mar;15(2):124-30. doi: 10.1016/j.cllc.2013.08.003. Epub 2013 Oct 26.


Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.

Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P.

Cancer Cytopathol. 2013 Sep;121(9):500-7. doi: 10.1002/cncy.21288. Epub 2013 Mar 12.


MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.

Jin Y, Sun PL, Kim H, Seo AN, Jheon S, Lee CT, Chung JH.

Ann Surg Oncol. 2014 Feb;21(2):621-8. doi: 10.1245/s10434-013-3355-1. Epub 2013 Nov 9.


Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T.

J Thorac Oncol. 2009 Jan;4(1):22-9. doi: 10.1097/JTO.0b013e3181914111.


Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.

J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa.


BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.

Karachaliou N, Costa C, Gimenez-Capitan A, Molina-Vila MA, Bertran-Alamillo J, Mayo C, Massuti B, Majem M, Carcereny E, Moran T, Sanchez JJ, Viteri S, Gasco A, Wannesson L, Souglakos J, Jimeno J, Rosell R; Spanish Lung Cancer Group.

J Thorac Oncol. 2013 Mar;8(3):295-300. doi: 10.1097/JTO.0b013e31827db621.


ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.

Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan Y, Hu H, Luo X, Ye T, Li H, Wang L, Chen H, Ji H.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S577-82. doi: 10.1245/s10434-013-3027-1. Epub 2013 Jun 18.


High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.

Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II.

J Thorac Oncol. 2012 May;7(5):833-40. doi: 10.1097/JTO.0b013e31824de09c. Erratum in: J Thorac Oncol. 2012 Jun;7(6):1065.


Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.


EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.

Sahnane N, Frattini M, Bernasconi B, Zappa F, Schiavone G, Wannesson L, Antonelli P, Balzarini P, Sessa F, Mazzucchelli L, Tibiletti MG, Martin V.

Clin Lung Cancer. 2016 Jan;17(1):56-61. doi: 10.1016/j.cllc.2015.08.001. Epub 2015 Aug 18.


EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.

Han HS, Eom DW, Kim JH, Kim KH, Shin HM, An JY, Lee KM, Choe KH, Lee KH, Kim ST, Koo JH, Lee HC, Lee OJ.

Clin Lung Cancer. 2011 Nov;12(6):380-6. doi: 10.1016/j.cllc.2011.02.006. Epub 2011 May 20.


EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.

Schweiger T, Hegedüs B, Nikolowsky C, Hegedüs Z, Szirtes I, Mair R, Birner P, Döme B, Lang G, Klepetko W, Ankersmit HJ, Hoetzenecker K.

Ann Surg Oncol. 2014 Mar;21(3):946-54. doi: 10.1245/s10434-013-3386-7. Epub 2013 Nov 27.


Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.

Yanagawa N, Leduc C, Kohler D, Saieg MA, John T, Sykes J, Yoshimoto M, Pintilie M, Squire J, Shepherd FA, Tsao MS.

J Thorac Oncol. 2012 Oct;7(10):1513-21.


Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.

J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.


Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.

Planck M, Isaksson S, Veerla S, Staaf J.

Clin Cancer Res. 2013 Sep 15;19(18):5116-26. doi: 10.1158/1078-0432.CCR-13-0928. Epub 2013 Aug 12.


Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.

Carneiro JG, Couto PG, Bastos-Rodrigues L, Bicalho MA, Vidigal PV, Vilhena A, Amaral NF, Bale AE, Friedman E, De Marco L.

Genet Res (Camb). 2014;96:e002. doi: 10.1017/S0016672314000032. Epub 2014 Mar 5.


Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.

Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K, Yasumoto K.

J Thorac Oncol. 2010 May;5(5):591-6. doi: 10.1097/JTO.0b013e3181d0a4db.


Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

Supplemental Content

Support Center